Sunday , July 22 2018
Home / Resources / Articles / Exercise Pill Offers Fitness Without Effort

Exercise Pill Offers Fitness Without Effort

Aug 5, 2008

Is this the magic pill we have all been waiting for? Can you enjoy the benefits of exercise without the pain of exertion? Forget treadmills and spin classes? The answer may one day be yes — just take a pill that tricks the muscles into thinking they have been working out furiously. Researchers at the Salk Institute report they have found two drugs that do wonders for the athletic endurance of couch potato mice. One drug, known as Aicar, increased the mice’s endurance on a treadmill by 44 percent after just four weeks of treatment.

A second drug, GW1516, supercharged the mice to a 75 percent increase in endurance, but had to be combined with exercise to have any effect.

“It’s a little bit like a free lunch without the calories,” said Dr. Ronald Evans, leader of the Salk group.

The results, Evans said, seem reasonably likely to apply to people, who control muscle tone with the same underlying genes as do mice. And if the drugs work and prove to be safe, they could be useful in a wide range of settings. They should help people who are too frail to exercise and those with health problems such as diabetes that are improved with exercise, he said.

Previous work with genetically engineered mice in the Evans lab had revealed that permanently activating a genetic switch known as PPAR delta turned mice into indefatigable marathon runners. In addition to their super-endurance, the altered mice were resistant to weight gain, even when fed a high-fat diet that caused obesity in ordinary mice. On top of their lean and mean physique, their response to insulin improved, lowering levels of circulating glucose.

But such muscle-enhancing drugs would also have obvious appeal to athletes seeking to gain an edge in performance. With funds from the Howard Hughes Medical Institute, Evans has devised test to detect whether an athlete has taken the drugs, and has made it available to the World Anti-Doping Agency, which prepares a list of forbidden substances for the International Olympic Committee.

Experts not involved in the study agreed that the drugs held promise for treating disease. Dr. Johan Auwerx, a specialist in metabolic diseases at the University Louis Pasteur in Strasbourg, France, said the result with the Aicar drug “looks pretty good’ and could be very helpful in the treatment of diabetes and obesity. “The fact you can mimic exercise is a big advantage because diet and exercise are the pillars of diabetes treatment,” he said.

Dr. Richard Bergman, an expert on obesity and diabetes at the University of Southern California, said the drugs could become widely used if they prove safe. “It is possible that the couch potato segment of the population might find this to be a good regimen, and of course that is a large number of people,” he said.

The idea of a workout in a pill seems almost too good to be true, but Evans has impressive research credentials, including winning the Lasker award, which often presages a Nobel prize. He is an expert on how hormones work in cells, and on a powerful gene-controlling protein called PPAR-delta which instructs fat cells to burn off fat.

Four years ago he found that PPAR-delta played a different role in muscle. Muscle fibers exist in two main forms. Type 1 fibers have copious numbers of mitochondria, the organelles that generate the cell’s energy, and are therefore resistant to fatigue. Type 2 fibers have fewer mitochondria and tire easily. Athletes have lots of Type 1 fibers, and people with obesity and diabetes have far fewer Type 1 and more Type 2 fibers.

Evans and his team found that PPAR-delta remodels the muscle, producing more of the high endurance type of fiber. They genetically engineered a strain of mice whose muscles produced extra amounts of PPAR-delta. These mice grew more Type 1 fibers and could run twice as far as on a treadmill as ordinary mice before collapsing.

Given that people cannot be improved in this way, Evans wondered if levels of the gene-controlling protein could be raised by drugs. Pharmaceutical companies have long tried to manipulate the protein because of its role in fat metabolism, and Evans found several drugs were already available, although they had been tested for different purposes.

In a report published in Cell, he describes the two drugs that successfully activate the muscle-remodeling system in mice. One, GW1516, activates PPAR-delta but the mice must also have exercise training to show increased endurance. It seems that PPAR-delta switches on one set of genes, and exercise another, and both sets are needed for great endurance.

The second drug, called Aicar, improves endurance without any training. Evans believes it both mimics the effects of exercise and activates PPAR-delta, thus being able to switch on both sets of genes needed for the endurance signal.

Aicar works by mimicking a by-product of energy metabolism, signaling the cell that it has burned off energy and needs to generate more. The drug is “pretty much pharmacological exercise,” Evans said.

He said the drugs work off a person’s own genetics, pushing the body to an improved set-point that is otherwise gained only by strenuous training. “This is not just a free lunch, it’s pushing your genome toward a more enhanced genetic tone that impacts metabolism and muscle function. So instead of inheriting a great set-point you are using a drug to move your own genetics to a more activated metabolic state.”

Aicar is a well known chemical that has been tested for various diseases since 1994. But neither Aicar nor GW1516 has been tested in people for muscle endurance so the health effects of the drugs, particularly over the long term, are not precisely known.

This may change if pharmaceutical companies pursue Evans’s findings. “The drugs’ effect on muscle opens a window to a world of medical problems,” Evans said. “This paper will alert the medical community that muscle can be a therapeutic target.”

The new drugs activate at least one of the pathways triggered by resveratrol, a substance found in red wine though in amounts probably too low to significantly affect muscle.

In 2006 Auwerx and colleagues showed that large doses of resveratrol would make mice run twice as far as usual on a treadmill before collapsing. It is unclear just how resveratrol works, but one of its effects may be to bind with a protein that helps activate PPAR-delta. Auwerx’s resveratrol-treated mice remodeled their muscle fibers into a type that contains larger numbers of the energy-producing mitochondria.

This is the same result that Evans has found can be obtained with Aicar.

The study was supported by the Howard Hughes Medical Institute, the Hillblom Foundation and the National Institute of Health.  Journal Cell July 31th, 2008